These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 8865474

  • 1. Use of prostate-specific antigen (PSA) and PSA density in the detection of stage T1 carcinoma of the prostate.
    Presti JC, Carroll PR.
    Semin Urol Oncol; 1996 Aug; 14(3):134-8. PubMed ID: 8865474
    [Abstract] [Full Text] [Related]

  • 2. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
    Presti JC, Hovey R, Carroll PR, Shinohara K.
    J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
    [Abstract] [Full Text] [Related]

  • 3. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D, Kamil ST, Pakasi LS.
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
    [Abstract] [Full Text] [Related]

  • 4. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
    Freedland SJ, Mangold LA, Epstein JI, Partin AW.
    Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
    [Abstract] [Full Text] [Related]

  • 5. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J, Raventós CX, Lorente JA, Lopez-Pacios MA, Encabo G, de Torres I, Andreu J.
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [Abstract] [Full Text] [Related]

  • 6. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S, Cakar B, Conkbayir I, Hekimoglu B.
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [Abstract] [Full Text] [Related]

  • 7. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [Abstract] [Full Text] [Related]

  • 8. [Value of determining prostate-specific antigen for early detection or prostatic carcinoma].
    Hammerer P, Huland H.
    Urologe A; 1995 Jul; 34(4):283-9. PubMed ID: 7545842
    [Abstract] [Full Text] [Related]

  • 9. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME.
    Clin Lab Sci; 2001 Jul; 14(2):102-7. PubMed ID: 15625982
    [Abstract] [Full Text] [Related]

  • 10. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
    Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T.
    Cancer; 2003 Oct 01; 98(7):1417-22. PubMed ID: 14508828
    [Abstract] [Full Text] [Related]

  • 11. [Screening of cancer of the prostate: study in a Spanish population].
    Herrero Payo JA, Montes Díaz MJ, Páez Borda A, Sánchez Sánchez E, Moreno Valle JA, Berenguer Sánchez A.
    Arch Esp Urol; 1996 Oct 01; 49(6):595-606. PubMed ID: 8929102
    [Abstract] [Full Text] [Related]

  • 12. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
    Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schröder FH.
    J Urol; 1997 Jun 01; 157(6):2191-6. PubMed ID: 9146612
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S, Charoenkraikamol C, Toraksa S, Uiprasertkul M, Amornvesukit T, Taweemonkongsap T, Udompunturak S, Nualyong C, Tantiwong A.
    J Med Assoc Thai; 2006 Jan 01; 89(1):37-42. PubMed ID: 16583579
    [Abstract] [Full Text] [Related]

  • 14. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
    Zlotta AR, Remzi M, Snow PB, Schulman CC, Marberger M, Djavan B.
    J Urol; 2003 May 01; 169(5):1724-8. PubMed ID: 12686818
    [Abstract] [Full Text] [Related]

  • 15. [Early detection of prostate carcinoma. What diagnosis is of value when?].
    Altwein JE, Mohandessi B.
    MMW Fortschr Med; 2000 Mar 16; 142(11):28-31. PubMed ID: 10786085
    [Abstract] [Full Text] [Related]

  • 16. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
    Iwaki H, Kajita Y, Shimizu Y, Yamauchi T.
    Hinyokika Kiyo; 2001 Mar 16; 47(3):169-74. PubMed ID: 11329957
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
    Bermúdez-Tamayo C, Martín Martín JJ, González Mdel P, Pérez Romero C.
    Urol Int; 2007 Mar 16; 79(4):336-44. PubMed ID: 18025853
    [Abstract] [Full Text] [Related]

  • 18. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
    Ito K, Kubota Y, Yamamoto T, Suzuki K, Fukabori Y, Kurokawa K, Yamanaka H.
    Cancer; 2001 Feb 15; 91(4):744-51. PubMed ID: 11241242
    [Abstract] [Full Text] [Related]

  • 19. Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer.
    Galić J, Karner I, Cenan L, Tucak A, Hegedus I, Pasini J, Bilandzija-Peranović M, Mihaljević S.
    Coll Antropol; 2003 Feb 15; 27 Suppl 1():61-6. PubMed ID: 12955893
    [Abstract] [Full Text] [Related]

  • 20. The current role of prostatic acid phosphatase and prostate-specific antigen in the management of prostate cancer.
    Shetty SD, Cerny JC.
    Henry Ford Hosp Med J; 1992 Feb 15; 40(1-2):93-8. PubMed ID: 1385363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.